Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lessened by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 214,097 shares of the biopharmaceutical company’s stock after selling 72,448 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Regeneron Pharmaceuticals were worth $152,508,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Larson Financial Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 28 shares in the last quarter. Finally, Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on REGN shares. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $637.36 on Friday. The firm has a market capitalization of $69.68 billion, a PE ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $629.02 and a 1 year high of $1,211.20. The firm’s fifty day simple moving average is $683.88 and its 200 day simple moving average is $800.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.86 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.